Dopamine D2/3 receptor occupancy of apomorphine in the nonhuman primate brain - A comparative PET study with [11C]raclopride and [11C]MNPA

Synapse

Volumn 63, Issue 5, 2009, Pages 378-389

  Finnema, Sjoerd J ^a,e   Halldin, Christer ^a   Bang Andersen, Benny ^b   Gulyás, Balázs ^a   Bundgaard, Christoffer ^b   Wikström, Håkan V ^c   Farde, Lars ^a,d  

^a KAROLINSKA INSTITUTE   (Sweden)

^b H LUNDBECK A S   (Denmark)

^c Allbay AB ^*  (Sweden)

^d ASTRAZENECA R AND D   (Sweden)

^e KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

D2 3 agonist; High affinity state; Monkey; Parkinson's disease

Indexed keywords

APOMORPHINE; DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR; RACLOPRIDE C 11; RADIOLIGAND;

ARTICLE; BINDING AFFINITY; CEREBELLUM; COMPARATIVE STUDY; CONTROLLED STUDY; CORPUS STRIATUM; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG DOSE INCREASE; DRUG ELIMINATION; DRUG HALF LIFE; DRUG RECEPTOR BINDING; LIGAND BINDING; MACACA; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RADIOACTIVITY; RECEPTOR OCCUPANCY;

ANIMALS; APOMORPHINE; BRAIN; CARBON RADIOISOTOPES; FEMALE; MACACA FASCICULARIS; POSITRON-EMISSION TOMOGRAPHY; PROTEIN BINDING; RACLOPRIDE; RECEPTORS, DOPAMINE D2; RECEPTORS, DOPAMINE D3; TISSUE DISTRIBUTION;

EID: 66049089990     PISSN: 08874476     EISSN: 10982396     Source Type: Journal    
DOI: 10.1002/syn.20615     Document Type: Article

References (79)

1. Aalto S, Hirvonen J, Kajander J, Scheinin H, Nagren K, Vilkman H, Gustafsson L, Syvalahti E, Hietala J. 2002. Ketamine does not decrease striatal dopamine D2 receptor binding in man. Psychopharmacology (Berl) 164:401-406.
2. Adams BW, Bradberry CW, Moghaddam B. 2002. NMDA antagonist effects on striatal dopamine release: Microdialysis studies in awake monkeys. Synapse 43:12-18.
3. 11C]raclopride and positron emission tomography in previously untreated patients with Parkinson's disease: Influence of L-dopa and lisuride therapy on striatal dopamine D2-receptors. Neurology 44:1325-1329.
4. Bibbiani F, Costantini LC, Patel R, Chase TN. 2005. Continuous dopaminergic stimulation reduces risk of motor complications in parkinsonian primates. Exp Neurol 192:73-78.
5. Breier A, Adler CM, Weisenfeld N, Su TP, Elman I, Picken L, Malhotra AK, Pickar D. 1998. Effects of NMDA antagonism on striatal dopamine release in healthy subjects: Application of a novel PET approach. Synapse 29:142-147.
6. 11C]raclopride as measured by PET. Synapse 51:27-31.
7. 11C]raclopride in anesthetized monkeys. In: Gjedde A, Hansen S, Knudsen G, Paulson O, editors. Physiological imaging of the brain with PET. San Diego: Academic Press. p 205-209.
8. 3H] spiperone binding: Evidence for accumulation in corpus striatum by agonist-mediated receptor internalization. J Cereb Blood Flow Metab 8:291-303.
9. Clark JD, Baldwin RL, Bayne KA, Brown MJ, Gebhart GF, Gonder JC, Gwathmey JK, Keeling ME, Kohn DF, Robb JW, Smith OA, Steggerda J-AD, VandeBergh JL. 1996. Guide for the care and use of laboratory animals. Washington, DC: National Academies Press.
10. 3H]propyl- norapomorphine to dopamine receptors in living mouse striatum: Occupancy by endogenous dopamine and guanosine triphosphatefree G protein. J Cereb Blood Flow Metab 22:596-604.
11. Cumming P, Wong DF, Dannals RF, Gillings N, Hilton J, Scheffel U, Gjedde A. 2002b. The competition between endogenous dopamine and radioligands for specific binding to dopamine receptors. Ann N Y Acad Sci 965:440-450.
12. Davies B, Morris T. 1993. Physiological parameters in laboratory animals and humans. Pharm Res 10:1093-1095.
13. de La Fuente-Fernandez R, Lim AS, Sossi V, Holden JE, Calne DB, Ruth TJ, Stoessl AJ. 2001. Apomorphine-induced changes in synaptic dopamine levels: Positron emission tomography evidence for presynaptic inhibition. J Cereb Blood Flow Metab 21:1151-1159.
14. De Lean A, Kilpatrick BF, Caron MG. 1982. Dopamine receptor of the porcine anterior pituitary gland. Evidence for two affinity states discriminated by both agonists and antagonists. Mol Pharmacol 22:290-297.
15. Farde L, Hall H, Ehrin E, Sedvall G. 1986. Quantitative analysis of D2 dopamine receptor binding in the living human brain by PET. Science 231:258-261.
16. Farde L, Wiesel FA, Jansson P, Uppfeldt G, Wahlen A, Sedvall G. 1988. An open label trial of raclopride in acute schizophrenia. Confirmation of D2-dopamine receptor occupancy by PET. Psychopharmacology (Berl) 94:1-7.
17. 2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects. Arch Gen Psychiatry 49:538-544.
18. 11C]MNPA in cynomolgus monkey. Nucl Med Biol 32:353-360.
19. 3H]MNPA from the precursor (R)-2-hydroxy-10,11-acetonide-NPA. J Labelled Compd Radiopharm 50:S201.
20. George SR, Watanabe M, Di Paolo T, Falardeau P, Labrie F, Seeman P. 1985. The functional state of the dopamine receptor in the anterior pituitary is in the high affinity form. Endocrinology 117:690-697.
21. 11C]raclopride Displacement Studies: Understanding the True Mechanism. Mol Imaging Biol 7:45-52.
22. 2-dopamine receptors in the monkey brain. Synapse 25:321-325.
23. 11C]raclopride positron emission tomography study in cats. Biol Psychiatry 55:1188-1194.
24. 2 receptors in vivo using positron emission tomography. J Neurochem 97:1089-1103.
25. Goggi JL, Sardini A, Egerton A, Strange PG, Grasby PM. 2007. Agonist- dependent internalization of D2 receptors: Imaging quantification by confocal microscopy. Synapse 61:231-241.
26. 3 receptors expressed in Chinese hamster ovary (CHO) cells. Biochem Pharmacol 58:285-289.
27. Harder S, Baas H, Demisch L, Simon E. 1998. Dose response and concentration response relationship of apomorphine in patients with Parkinson's disease and end-of-dose akinesia. Int J Clin Pharmacol Ther 36:355-362.
28. 11C]raclopride binding in the striatum of the awake cat: Effects of anaesthetics and role of cerebral blood flow. Eur J Nucl Med Mol Imaging 30:141-148.
29. 11C]raclopride in anaesthetised rodents. Synapse 51:206-212.
30. 2 receptors. Nucl Med Biol 27:533-539.
31. 11C]DASB positron emission tomography studies of the serotonin transporter in human brain. J Cereb Blood Flow Metab 23:1096-1112.
32. 123I]IBZM binding to the D2 receptor in nonhuman primates. Synapse 10:177-184.
33. Innis RB, Cunningham VJ, Delforge J, Fujita M, Gjedde A, Gunn RN, Holden J, Houle S, Huang SC, Ichise M, Iida H, Ito H, Kimura Y, Koeppe RA, Knudsen GM, Knuuti J, Lammertsma AA, Laruelle M, Logan J, Maguire RP, Mintun MA, Morris ED, Parsey R, Price JC, Slifstein M, Sossi V, Suhara T, Votaw JR, Wong DF, Carson RE. 2007. Consensus nomenclature for in vivo imaging of reversibly binding radioligands. J Cereb Blood Flow Metab 27: 1533-1539.
34. 2 receptors. Eur J Pharmacol 540:53-56.
35. 2 receptors-implications for models of schizophrenia. Mol Psychiatry 7:837-844.
36. 2 occupancy, clinical response, and side effects: A double-blind PET study of first-episode schizophrenia. Am J Psychiatry 157:514-520.
37. Kapur S, Zipursky R, Jones C, Shammi CS, Remington G, Seeman P. 2000b. A positron emission tomography study of quetiapine in schizophrenia: A preliminary finding of an antipsychotic effect with only transiently high dopamine D2 receptor occupancy. Arch Gen Psychiatry 57:553-559.
38. 1-dopamine receptor. Psychopharmacology (Berl) 113:149-156.
39. Kegeles LS, Abi-Dargham A, Zea-Ponce Y, Rodenhiser-Hill J, Mann JJ, Van Heertum RL, Cooper TB, Carlsson A, Laruelle M. 2000. Modulation of amphetamine-induced striatal dopamine release by ketamine in humans: Implications for schizophrenia. Biol Psychiatry 48:627-640.
40. Kegeles LS, Martinez D, Kochan LD, Hwang DR, Huang Y, Mawlawi O, Suckow RF, Van Heertum RL, Laruelle M. 2002. NMDA antagonist effects on striatal dopamine release: Positron emission tomography studies in humans. Synapse 43:19-29.
41. Kenakin T. 1997. Differences between natural and recombinant G protein-coupled receptor systems with varying receptor/G protein stoichiometry. Trends Pharmacol Sci 18:456-464.
42. 11C]raclopride-a positron emission tomography study in Macaca mulatta. J Cereb Blood Flow Metab 24:531-535.
43. 11C]methyl triflate. J Labelled Compd Radiopharm 42:1183-1193.
44. Laruelle M. 2000. Imaging synaptic neurotransmission with in vivo binding competition techniques: A critical review. J Cereb Blood Flow Metab 20:423-451. (Pubitemid 30164887)
45. Laruelle M, Iyer RN, al-Tikriti MS, Zea-Ponce Y, Malison R, Zoghbi SS, Baldwin RM, Kung HF, Charney DS, Hoffer PB, Innis RB, Bradberry CW. 1997. Microdialysis and SPECT measurements of amphetamine-induced dopamine release in nonhuman primates. Synapse 25:1-14.
46. 3H]raclopride are indistinguishably inhibited by D2 agonists and antagonists ex vivo. Nucl Med Biol 35:11-17.
47. 2 receptor agonists correlates with preferential coupling to cyclic AMP. Neuroreport 12:1473-1479.
48. Millan MJ, Maiofiss L, Cussac D, Audinot V, Boutin JA, Newman-Tancredi A. 2002. Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. I. A multivariate analysis of the binding profiles of 14 drugs at 21 native and cloned human receptor subtypes. J Pharmacol Exp Ther 303:791-804.
49. 11C]-raclopride. Synapse 52:188-208.
50. Narendran R, Hwang DR, Slifstein M, Hwang Y, Huang Y, Ekelund J, Guillin O, Scher E, Martinez D, Laruelle M. 2005. Measurement of the proportion of D2 receptors configured in state of high affinity for agonists in vivo: A positron emission tomography study using [11C]N-propyl-norapomorphine and [11C]raclopride in baboons. J Pharmacol Exp Ther 315:80-90.
51. 11C]NPA) in an anesthetized nonhuman primate. Synapse 61:106-109.
52. Neef C, van Laar T. 1999. Pharmacokinetic-pharmacodynamic relationships of apomorphine in patients with Parkinson's disease. Clin Pharmacokinet 37:257-271.
53. 11C]raclopride binding in healthy young adults and schizophrenic patients - reliability and age effects. Human Psychopharmacology 7:157-165.
54. Obering CD, Chen JJ, Swope DM. 2006. Update on apomorphine for the rapid treatment of hypomobility ("off") episodes in Parkinson's disease. Pharmacotherapy 26:840-852.
55. 35S]guanosine 5′-O-(gamma-thiotriphosphate) binding in rat striatal membranes. Prog Neuropsychopharmacol Biol Psychiatry 30:1304-1312.
56. 1 receptor agonists. Mol Pharmacol 68:1039-1048.
57. Schwarz J, Oertel WH, Tatsch K. 1996. Iodine-123-iodobenzamide binding in parkinsonism: Reduction by dopamine agonists but not L-Dopa. J Nucl Med 37:1112-1115.
58. 2High receptors. Synapse 61:1013-1018.
59. Seeman P, Kapur S. 2003. Anesthetics inhibit high-affinity states of dopamine D2 and other G-linked receptors. Synapse 50:35-40.
60. 2 high receptors occupied by endogenous dopamine, even in the absence of acute challenges. Synapse 46:235-239.
61. 3H]spiperone in isotonic medium: Implications for human positron emission tomography. Synapse 49:209-215.
62. 2High states, implying many paths to psychosis. Proc Natl Acad Sci USA 102:3513-3518.
63. Seeman P, Ko F, Willeit M, McCormick P, Ginovart N. 2005b. Antiparkinson concentrations of pramipexole and PHNO occupy dopamine D2high and D3high receptors. Synapse 58:122-128.
64. Seeman P, Ko F, Tallerico T. 2005c. Dopamine receptor contribution to the action of PCP, LSD and ketamine psychotomimetics. Mol Psychiatry 10:877-883.
65. 2high dopamine receptors. Synapse 60:319-346.
66. 11C]raclopride. Synapse 59:260-269.
67. Sibley DR, De Lean A, Creese I. 1982. Anterior pituitary dopamine receptors. Demonstration of interconvertible high and low affinity states of the D-2 dopamine receptor. J Biol Chem 257:6351-6361.
68. 11C-raclopride in normal human subjects. Neuropsychopharmacology 18:18-25.
69. 11C]MNPA from the precursor (R)-(-)-2-Hydroxy-10,11-Acetonide-NPA and a preliminary test-retest PET analysis in monkey brain. Neuroimage 41:T102.
70. 3H]spiperone. Mol Pharmacol 63:456-462.
71. Tsukada H, Nishiyama S, Kakiuchi T, Ohba H, Sato K, Harada N, Nakanishi S. 1999. Isoflurane anesthesia enhances the inhibitory effects of cocaine and GBR12909 on dopamine transporter: PET studies in combination with microdialysis in the monkey brain. Brain Res 849:85-96.
72. 11C]raclopride binding with no alterations in static dopamine concentrations in the striatal extracellular fluid in the monkey brain: Multiparametric PET studies combined with microdialysis analysis. Synapse 37:95-103.
73. 11C]raclopride binding in unanesthetized monkeys. Synapse 45:207-212.
74. Verma A, Moghaddam B. 1996. NMDA receptor antagonists impair prefrontal cortex function as assessed via spatial delayed alternation performance in rats: Modulation by dopamine. J Neurosci 16:373-379. (Pubitemid 26010723)
75. 123I]IBZM as measured with SPECT in MPTP monkeys. Synapse 17:115-124.
76. 11C]raclopride PET study of a model psychosis in humans. J Psychiatr Res 34:35-43.
77. Wienhard K, Dahlbom M, Eriksson L, Michel C, Bruckbauer T, Pietrzyk U, Heiss WD. 1994. The ECAT EXACT HR: Performance of a new high resolution positron scanner. J Comput Assist Tomogr 18:110-118.
78. 11C]-(1)-4-propyl-3,4,4a,5,6,10b-hexahydro-2H-naphtho[ 1,2-b][1,4]oxazin-9 -ol as a potential radiotracer for in vivo imaging of the dopamine D2 high-affinity state with positron emission tomography. J Med Chem 48:4153-4160.
79. Zetterstrom T, Ungerstedt U. 1984. Effects of apomorphine on the in vivo release of dopamine and its metabolites, studied by brain dialysis. Eur J Pharmacol 97:29-36.